MarketPulse

GLP-1 drugs

24 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Oral Weight-Loss Drug Expands Market Rather Than Cannibalizing Sales

Oral weight-loss drugs expand the market rather than cannibalizing injectables, attracting new patients. However, Novo Nordisk expects 2026 revenue headwinds from competition and pricing pressures.
LLYNVOGLP-1 drugspharmaceutical competition
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Intuitive Surgical Posts Double-Digit Growth Despite GLP-1 Drug Market Spotlight

Intuitive Surgical posts double-digit growth in 2025 with 12% installed base expansion and 18% surgery increase, unaffected by GLP-1 drug market competition.
LLYNVOISRGGLP-1 drugsgrowth stocks
The Motley FoolThe Motley Fool··Matthew Benjamin

Eli Lilly Positions Itself as Pharma Leader Through GLP-1 Dominance and Strategic M&A

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.
PFELLYacquisitionsgene therapy
The Motley FoolThe Motley Fool··Matthew Benjamin

Eli Lilly Acquires Orna Therapeutics for $2.4B to Expand Gene Therapy Pipeline

Eli Lilly acquires Orna Therapeutics for $2.4B to gain circular RNA gene therapy technology and autoimmune disease candidates, strengthening its pipeline.
MRKLLYacquisitionclinical trials